# Mavacamten

Drug · id `cardio:mavacamten` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Camzyos

Browse, condition area: Heart failure  

## In plain language

Mavacamten is the medicine inside Camzyos. The US label describes it as a reversible blocker of cardiac myosin, a protein of the heart muscle. The label gives its indication as symptomatic obstructive hypertrophic cardiomyopathy: for adults with class II-III symptoms in the older label version read, and for adults and pediatric patients who weigh at least 30 kg in the latest version read. A boxed warning says it can cause heart failure, and it can be obtained only through a restricted safety program. The atlas holds no trial results for it.

## Technical summary

RxNorm ingredient 2600867. FDA application NDA214998, brand name Camzyos. The mechanism comes from version 8 of the label in the openFDA record (a reversible, allosteric blocker acting selectively on cardiac myosin). Version 9 on DailyMed, effective 30 September 2026, was the latest read; its indication wording differs from version 8, and the Drugs@FDA record lists an efficacy supplement approved on the same date, though it does not say what that supplement changed.

## Claims, with the population each applies to

## Context: Adults, and in the latest label also pediatric patients who weigh at least 30 kg, who have symptomatic obstructive hypertrophic cardiomyopathy, as described in the US label of Camzyos

Recipient: Mixed recipients; Population: People with symptomatic obstructive hypertrophic cardiomyopathy. The openFDA copy of the label (version 8, effective 2025-04-17) names adults with symptomatic New York Heart Association (NYHA) class II-III disease. The DailyMed label (version 9, effective 2026-09-30) names adults and pediatric patients who weigh at least 30 kg.; Care setting: Prescription medicine under a restricted program; the label records state the program but not a care setting; Geography: United States (labeling approved by the US Food and Drug Administration); Life stage: Adults in version 8 of the label; adults and pediatric patients who weigh at least 30 kg in version 9. The records give no other age limit.; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory and labeling statement)

### The Camzyos label carries a boxed warning of the risk of heart failure. It says Camzyos lowers the left ventricular ejection fraction and can lead to heart failure from weakened pumping (systolic dysfunction). Version 8 of the label (openFDA) states that the medicine can be obtained only through a restricted safety program set up under a Risk Evaluation and Mitigation Strategy, and version 9 (DailyMed) describes the same restricted program.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Mixed recipients; Population: People with symptomatic obstructive hypertrophic cardiomyopathy. The openFDA copy of the label (version 8, effective 2025-04-17) names adults with symptomatic New York Heart Association (NYHA) class II-III disease. The DailyMed label (version 9, effective 2026-09-30) names adults and pediatric patients who weigh at least 30 kg.; Care setting: Prescription medicine under a restricted program; the label records state the program but not a care setting; Geography: United States (labeling approved by the US Food and Drug Administration); Life stage: Adults in version 8 of the label; adults and pediatric patients who weigh at least 30 kg in version 9. The records give no other age limit.; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory and labeling statement)
- Limitations: This claim records the headline of the boxed warning only. The warning also covers ejection fraction checks and interacting medicines, which are not recorded here. The DailyMed label is cite only, so its wording is paraphrased. openFDA says not to rely on its data for decisions about medical care. The atlas gives no dose.
- Last checked: 2026-10-30
- Sources:
  1. Supports: Camzyos drug label (openFDA record, set id 669c936b-3ee6-4e36-8a22-79dd11b1255b, version 8) (Label, edition openFDA drug label record, label version 8, effective 20250417, dataset last updated 2026-10-30. This copy is older than the label on DailyMed, which was version 9 effective 20260930 when read on 2026-10-30 (see cardio:dailymed-label-669c936b-3ee6-4e36-8a22-79dd11b1255b). The two versions state the indication differently.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=669c936b-3ee6-4e36-8a22-79dd11b1255b>
     Locator: results\[0\].boxed\_warning\[0\]. Retrieved 2026-10-30T19:47:57Z. Source state: Current. Version fingerprint: 78fe53bfe25e2c043bd661aad42fa246457021432aaeb27721c641e8f2e639fb.
     How it applies: Boxed warning in label version 8.
  2. Supports: Camzyos drug label (DailyMed SPL, set id 669c936b-3ee6-4e36-8a22-79dd11b1255b, version 9) (Label, edition DailyMed structured product label, version 9, effective 20260930, fetched as XML from the DailyMed web service on 2026-10-30. The DailyMed listing for the set id gave the same version (published Oct 12, 2026).) <https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/669c936b-3ee6-4e36-8a22-79dd11b1255b.xml>
     Locator: Boxed warning. Retrieved 2026-10-30T19:55:31Z. Source state: Current. Version fingerprint: e081aa570e068b67ff424c4b28bfd0d79e871a2d88c6c4e0744666549f31fb6c.
     How it applies: Boxed warning in label version 9.
  3. Supports: Camzyos drug label (DailyMed SPL, set id 669c936b-3ee6-4e36-8a22-79dd11b1255b, version 9) (Label, edition DailyMed structured product label, version 9, effective 20260930, fetched as XML from the DailyMed web service on 2026-10-30. The DailyMed listing for the set id gave the same version (published Oct 12, 2026).) <https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/669c936b-3ee6-4e36-8a22-79dd11b1255b.xml>
     Locator: Boxed warning, restricted program. Retrieved 2026-10-30T19:55:31Z. Source state: Current. Version fingerprint: e081aa570e068b67ff424c4b28bfd0d79e871a2d88c6c4e0744666549f31fb6c.
     How it applies: Restricted program in label version 9.

### The US Food and Drug Administration lists Camzyos (mavacamten) under new drug application NDA214998. The openFDA record names the applicant as BRISTOL and lists the original submission as approved on 28 April 2022 in the class Type 1 - New Molecular Entity. The copy of the label in the openFDA label record (version 8, effective 17 April 2025) says Camzyos is indicated for adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy, to improve functional capacity and symptoms. The label on DailyMed (version 9, effective 30 September 2026) states the indication for adults, and for pediatric patients who weigh at least 30 kg, who have symptomatic obstructive hypertrophic cardiomyopathy. The openFDA application record lists supplement 13, of class Efficacy, as approved on 30 September 2026, the same date as the DailyMed label.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Mixed recipients; Population: People with symptomatic obstructive hypertrophic cardiomyopathy. The openFDA copy of the label (version 8, effective 2025-04-17) names adults with symptomatic New York Heart Association (NYHA) class II-III disease. The DailyMed label (version 9, effective 2026-09-30) names adults and pediatric patients who weigh at least 30 kg.; Care setting: Prescription medicine under a restricted program; the label records state the program but not a care setting; Geography: United States (labeling approved by the US Food and Drug Administration); Life stage: Adults in version 8 of the label; adults and pediatric patients who weigh at least 30 kg in version 9. The records give no other age limit.; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory and labeling statement)
- Limitations: An FDA approval is a decision about a medicine, not a finding about how much it helps any person. The two label versions state the indication differently and the openFDA copy is the older one; the atlas gives both and treats the DailyMed text as the latest read. The records do not say what supplement 13 changed, so the link between that supplement and the new wording is an inference from the matching date. The DailyMed label is cite only, so its wording is paraphrased. openFDA says not to rely on its data for decisions about medical care. The atlas gives no dose.
- Last checked: 2026-10-30
- Sources:
  1. Supports: FDA drug application NDA214998 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214998&limit=1>
     Locator: results\[0\].application\_number. Retrieved 2026-10-30T19:45:00Z. Source state: Current. Version fingerprint: 972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71.
     How it applies: Application number.
  2. Supports: FDA drug application NDA214998 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214998&limit=1>
     Locator: results\[0\].sponsor\_name. Retrieved 2026-10-30T19:45:00Z. Source state: Current. Version fingerprint: 972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71.
     How it applies: Applicant.
  3. Supports: FDA drug application NDA214998 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214998&limit=1>
     Locator: results\[0\].products\[0\].brand\_name. Retrieved 2026-10-30T19:45:00Z. Source state: Current. Version fingerprint: 972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71.
     How it applies: Brand name.
  4. Supports: FDA drug application NDA214998 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214998&limit=1>
     Locator: results\[0\].products\[0\].active\_ingredients\[0\].name. Retrieved 2026-10-30T19:45:00Z. Source state: Current. Version fingerprint: 972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71.
     How it applies: Active ingredient.
  5. Supports: FDA drug application NDA214998 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214998&limit=1>
     Locator: results\[0\].submissions\[0\].submission\_type. Retrieved 2026-10-30T19:45:00Z. Source state: Current. Version fingerprint: 972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71.
     How it applies: Original submission.
  6. Supports: FDA drug application NDA214998 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214998&limit=1>
     Locator: results\[0\].submissions\[0\].submission\_status. Retrieved 2026-10-30T19:45:00Z. Source state: Current. Version fingerprint: 972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71.
     How it applies: Status of the original submission (AP is approved).
  7. Supports: FDA drug application NDA214998 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214998&limit=1>
     Locator: results\[0\].submissions\[0\].submission\_status\_date. Retrieved 2026-10-30T19:45:00Z. Source state: Current. Version fingerprint: 972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71.
     How it applies: Date of the original approval, written as eight digits.
  8. Supports: FDA drug application NDA214998 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214998&limit=1>
     Locator: results\[0\].submissions\[0\].submission\_class\_code\_description. Retrieved 2026-10-30T19:45:00Z. Source state: Current. Version fingerprint: 972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71.
     How it applies: Class of the original submission.
  9. Supports: FDA drug application NDA214998 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214998&limit=1>
     Locator: results\[0\].submissions\[3\].submission\_number. Retrieved 2026-10-30T19:45:00Z. Source state: Current. Version fingerprint: 972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71.
     How it applies: Supplement number.
  10. Supports: FDA drug application NDA214998 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214998&limit=1>
     Locator: results\[0\].submissions\[3\].submission\_status\_date. Retrieved 2026-10-30T19:45:00Z. Source state: Current. Version fingerprint: 972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71.
     How it applies: Date of supplement 13, written as eight digits.
  11. Supports: FDA drug application NDA214998 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA214998&limit=1>
     Locator: results\[0\].submissions\[3\].submission\_class\_code\_description. Retrieved 2026-10-30T19:45:00Z. Source state: Current. Version fingerprint: 972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71.
     How it applies: Class of supplement 13.
  12. Supports: Camzyos drug label (openFDA record, set id 669c936b-3ee6-4e36-8a22-79dd11b1255b, version 8) (Label, edition openFDA drug label record, label version 8, effective 20250417, dataset last updated 2026-10-30. This copy is older than the label on DailyMed, which was version 9 effective 20260930 when read on 2026-10-30 (see cardio:dailymed-label-669c936b-3ee6-4e36-8a22-79dd11b1255b). The two versions state the indication differently.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=669c936b-3ee6-4e36-8a22-79dd11b1255b>
     Locator: results\[0\].indications\_and\_usage\[0\]. Retrieved 2026-10-30T19:47:57Z. Source state: Current. Version fingerprint: 78fe53bfe25e2c043bd661aad42fa246457021432aaeb27721c641e8f2e639fb.
     How it applies: Indication in label version 8 (older copy).
  13. Supports: Camzyos drug label (DailyMed SPL, set id 669c936b-3ee6-4e36-8a22-79dd11b1255b, version 9) (Label, edition DailyMed structured product label, version 9, effective 20260930, fetched as XML from the DailyMed web service on 2026-10-30. The DailyMed listing for the set id gave the same version (published Oct 12, 2026).) <https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/669c936b-3ee6-4e36-8a22-79dd11b1255b.xml>
     Locator: Section 1, Indications and Usage. Retrieved 2026-10-30T19:55:31Z. Source state: Current. Version fingerprint: e081aa570e068b67ff424c4b28bfd0d79e871a2d88c6c4e0744666549f31fb6c.
     How it applies: Indication in label version 9 (latest read).

## Connected pages

- US label indication: symptomatic obstructive hypertrophic cardiomyopathy: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`) [a claim, not a settled fact; see claim `cardio:claim-mavacamten-label-indication` and its context]
- Filed under this front: Medicines (`cardio:front-medicines`)
- Related to: Aficamten (`cardio:aficamten`)
- Related to: Septal reduction therapy (myectomy, alcohol septal ablation) (`cardio:septal-reduction-therapy-myectomy-alcohol-septal-ablation`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 1 registry product
- 7 registry trials

## Provenance

Content hash: e8d7d1230f254f7964fbfc111b530de1f55166f3857d87db00b95596a4b744d5
Last substantive edit: 2026-10-30
Evidence last checked: 2026-10-30
